If we knew nothing about Algernon Pharmaceuticals (CSE: AGN) and we read their press release this morning about the Full Data Set of their successful Phase 2 Study of Ifenprodil for IPF and Chronic Cough and you told us that their clinical trials of DMT for stroke are launching shortly, we would guess that its market cap would already be in the $50-$100 million range. It's unbelievable to us that AGN's current market cap at $5.39 per share is only US$9.76 million.
Never in our careers have we discovered a higher quality company at a market cap of less than US$10 million.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
